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Abstract
Background: Adaptive designs are becoming increasingly important in clinical research. One
approach subdivides the study into several (two or more) stages and combines the p-values of the
different stages using Fisher's combination test.
Methods: Alternatively to Fisher's test, the recently proposed truncated product method (TPM)
can be applied to combine the p-values. The TPM uses the product of only those p-values that do
not exceed some fixed cut-off value. Here, these two competing analyses are compared.
Results: When an early termination due to insufficient effects is not appropriate, such as in dose-
response analyses, the probability to stop the trial early with the rejection of the null hypothesis is
increased when the TPM is applied. Therefore, the expected total sample size is decreased. This
decrease in the sample size is not connected with a loss in power. The TPM turns out to be less
advantageous, when an early termination of the study due to insufficient effects is possible. This is
due to a decrease of the probability to stop the trial early.
Conclusion: It is recommended to apply the TPM rather than Fisher's combination test whenever
an early termination due to insufficient effects is not suitable within the adaptive design.
Background
Randomized controlled experiments were introduced by
Sir Ronald A. Fisher in the 1920s for agricultural studies
and not in order to compare the effects of different treat-
ments in humans. However, according to Palmer [1] the
way clinical trials are conducted today is essentially
unchanged from Fisher's day. In contrast to agricultural
studies most clinical trials require periodic monitoring of
the accumulating data, e.g. to minimize the number of
experimental patients who will continue with an inferior
treatment [[2], p. 360].
Adaptive designs with at least one interim analysis can
potentially be used for periodic monitoring. All informa-
tion from the first stage(s) can be used to plan the follow-
ing stage(s). A number of adaptive designs have been
proposed recently, for an overview see Bauer et al. [3].
Here, we consider the adaptive procedure according to
Bauer and Köhne [4] that uses Fisher's product test.
Let k be the number of stages (i.e., there are k - 1 interim
analyses), and let pi be the one-sided p-value observed
with the i-th stage's data, i = 1, ..., k. According to Fisher's
product criterion [[5], pp. 37–39] the null hypothesis H0
can be rejected at the end of the trial if
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,
where   is the (1 - α)-quantile of the central χ2-
distribution with 2k degrees of freedom.
In clinical trials boundaries for early stopping after an
interim analysis may be incorporated. Obviously, in the
case of p1 ≤ cα early stopping with the rejection of H0 is
possible after stage one. In general, H0 can be rejected after
the j-th stage if  . In addition, one may termi-
nate the trial due to insufficient effects. A lower limit α0
can be included so that the trial is terminated without
rejecting H0 if p1 ≥ α0. According to Bauer and Köhne [[4],
p. 1031] a value of 0.5 may be a suitable choice for α0.
Bauer and Röhmel [[6], p. 1596] recommended α0 = 1 for
establishing a dose-response relationship, that is, no early
stopping without rejecting H0 at all. In this context, an
early stopping due to insufficient effects is not feasible
since doses in a plateau region could have been used. In
that case, different doses may be used in the following
stage.
Note that, in case of α0 < 1, larger boundaries for 
apply for early stopping with the rejection of H0. For a
two-stage design, one can reject H0 after stage one if p1 ≤
α1 for a value of α1 that lies between cα and α [4,6]. This
value can be calculated iteratively using the formula [[4],
p. 1032]
As an alternative to Fisher's product test, Zaykin et al. [7]
recently introduced a truncated product method for com-
bining p-values. To be precise, instead of calculating the
product of all p-values, they suggested the use of the prod-
uct of only those p-values that do not exceed some fixed
cut-off value τ, 0 < τ ≤ 1. The truncated product Wτ is
defined as
where I(.) is the indicator function. Since the p-values of
the different stages are independent,
[[7], p. 173] holds for w < 1 under the overall null hypoth-
esis (i.e., under the assumption that each stage's null
hypothesis is true). Figure 1 displays the rejection region
for k = 2 and τ = 0.5.
When using the truncated product method, the (1-α)-
quantile of the distribution of Wτ,  , is the critical value
for the combination test. Analogous to Fisher's combina-
tion test an   can be calculated for given α0 such that the
overall type I error rate is α.
Zaykin et al. [7] and Neuhäuser [8] investigated the trun-
cated product method for combining a large number of p-
values and demonstrated by simulation that it can pro-
vide high power. In this paper we investigate whether the
truncated product method is also useful for the adaptive
design described above. In contrast to previous applica-
tions [7,8] we consider classical experimental questions
involving only few p-values. Very recently, a rank trun-
cated product was proposed as a further alternative [9].
That method uses the product of the K most significant p-
values where K  can be chosen. Since we consider the
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The rejection region of the truncated product method for k  = 2 and τ = 0.5 Figure 1
The rejection region of the truncated product method for k 
= 2 and τ = 0.5.
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combination of 2 to 4 p-values only, the rank truncated
product does not seem to be appropriate for our aim.
We first present the comparison of the combinations with
and without truncation for designs with two stages. After-
wards, designs with more than two stages are investigated.
We then illustrate the method using two examples, and
conclusions are given in final section.
Methods
In order to compare the adaptive procedures with and
without truncation we consider the situation of two paral-
lel groups with means µ1 and µ2. There are 100 observa-
tions per stage. These observations are subdivided into
two groups and are assumed to be normally distributed
with a common, but unknown variance σ2. Student's t test
is performed in each of the two stages with a one-sided
significance level of α = 5%.
The overall p-value, i.e. the p-value of the combination
test, is defined as follows [10]: In case the study stops after
stage 1, the overall p-value equals p1. Otherwise, the over-
all p-value is   for Fisher's
combination test and
 for the truncated
product test.
The case α0 = 0.5
First, we consider a study that is terminated early due to
insufficient effects if p1 ≥ α0 = 0.5. Without any truncation
(i.e., τ = 1) we have cα = 0.0087 and α1 = 0.0233 in this
case [4]. However, when we set τ = α0 = 0.5, a smaller
value for α1  but a larger boundary for
 is obtained. To be precise,
the trial can be terminated early with the rejection of H0 if
p1 ≤   = 0.0190, and there is a significance at the end of
the trial if Wτ = 0.5 ≤   = 0.0095.
Although α1 is decreased the overall power can increase in
case of truncation as the boundary   for Wτ = 0.5 is larger
than that for Wτ = 1. Table I displays the overall power, that
is, the power to reject H0 after any stage, for different alter-
natives   (see the appendix for details about
the calculation of the power). The power is slightly higher
in case of truncation. The difference is very small when the
ratio (sample size in stage one)/(sample size in stage two)
is large. The reason is that the probability to stop already
after the first stage depends on the sample size in stage
one.
The area of the rejection region of Fisher's test that can be
relocated in case of α0 < 1 [[4], p.1032] has, under H0, the
probability Pr(p1 ≥ α0 and p1p2 ≤ cα) = cα(-lnα0). In case of
truncation with τ = α0, an area with probability Pr(p1 ≥ α0
and p2 ≤  ) =   (1 - τ) can be relocated. Since cα(-lnα0)
>   (1  -  τ) for practically relevant situations (see e.g.
Table II), we have   < α1. Hence, the probability to ter-
minate the trial after stage one is lower in case of trunca-
tion with τ = α0.
For instance, in the case of 50 observations per group and
stage and δ = 0.4 (α = 0.05) the probabilities to reject H0
after the first stage are Pr(p1 ≤ α1) = 0.496 and Pr(p1 ≤ )
= 0.461, respectively. The probability to stop without
rejecting H0 is Pr(p1 ≥ α0) = 0.023 irrespective of trunca-
tion. With the fixed sample size of 100 per stage the
expected total sample size is 200 - 100·Pr(stop after first
Table 1: Power to reject H0 in a two-stage design with α0 = 0.5 (combination of t tests, one-sided, α = 0.05)
δ = 0.1 0.2 0.3 0.4 0.5
25 observations per group in stage one, 75 observations per group in stage two
τ = 1 0.149 0.343 0.595 0.808 0.929
τ = 0.5 0.153 0.352 0.605 0.815 0.931
50 observations per group and stage
τ = 1 0.162 0.377 0.644 0.854 0.959
τ = 0.5 0.165 0.384 0.652 0.860 0.961
75 observations per group in stage one, 25 observations per group in stage two
τ = 1 0.166 0.386 0.654 0.860 0.962
τ = 0.5 0.167 0.389 0.657 0.863 0.963
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stage). This expected total sample size is 148 for τ = 1, but
152 in case of truncation. Hence, the slight increase in
power is connected with a larger expected total sample
size.
An a priori fixed sample size for stage two is uncommon
within an adaptive design. Instead, a sample size reassess-
ment can be carried out during the interim analysis [11].
Using p1 and the difference and variability observed in
stage one, we simulated the sample size for stage two
needed for an overall power of 80%. The results (not
shown) indicate that, in this case, the application of the
truncated product method can lead to a smaller expected
total sample size.
Nevertheless, there is still a smaller probability to stop the
trial after the first stage when the truncation is applied.
That is a clear disadvantage in clinical development where
early decisions are desirable. Therefore, despite the
(small) improvement in terms of power, a truncation
does not seem to be preferable within a two-stage adaptive
design when α0 < 1.
The case α0 = 1
As mentioned in the introduction, α0 = 1 can be a suitable
choice, for example when establishing a dose-response
relationship. The choice α0 = 1 leads to the same rejection
boundary cα for the interim and the final analysis, respec-
tively. Hence, there is α1 = cα and .  Since  cα <,
the expected total sample size is decreased due to trunca-
tion even in case of a fixed sample size for stage two. For
instance, in the case of 50 observations per group and
stage and δ = 0.4 (α = 0.05) the probability to reject H0
after the first stage is Pr(p1 ≤ α1) = 0.342 for τ = 1, but Pr(p1
≤  ) = 0.354 for τ = 0.5. The resultant expected total
sample sizes are 166 and 165, respectively. Therefore, a
gain in power would be of more importance in case α0 = 1.
However, as demonstrated in Figure 2 there is hardly any
difference in power between the choices τ = 0.5 and τ = 1.
Nevertheless, the application of the truncated product
method is preferable in the case α0 = 1 because there is a
lower expected total sample size and a higher probability
to reject H0 already after the first stage.
The value   increases with a decreasing truncation
point τ. Hence, in order to increase the probability to
reject H0 after stage one, one may argue that a smaller
value of τ is preferable. However, this is not the case
because the overall power depends on the choice of τ, too.
For example, consider 50 observations per group and
stage and δ = 0.4 (α = 0.05) again. In this case, the overall
power is 0.861 for τ = 1, 0.864 for τ = 0.5, but only 0.830
for τ = 0.2.
We now present results for adaptive designs with three
and four stages, respectively, and α0 = 1. Again, the behav-
iour of the strategies is investigated for fixed sample sizes
in the separate study stages without including the option
for sample size reassessment. The trial can be terminated
with the rejection of H0 after the j-th stage if   in
case of τ = 1 or if   in case of truncation.
Table 2: Boundaries cα and   for two to four stages
Number of stages (k) cα  for τ = 0.5
α = 0.025
2 0.00380 0.00408
3 0.00072 0.00085
4 0.00015 0.00020
α = 0.05
2 0.00870 0.00948
3 0.00184 0.00222
4 0.00042 0.00057
 cα
 cα
 α α 1 = c  cα
 α1
Power to reject H0 in a two-stage design with α0 = 1 Figure 2
Power to reject H0 in a two-stage design with α0 = 1. (50 
observations per group and stage, combination of t tests, 
one-sided, α = 0.05)
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For up to four stages, Table II displays the boundaries cα
and   for  τ = 0.5.
The choices τ = 1 and τ = 0.5 were compared in a Monte
Carlo simulation study performed using SAS version 8.2.
For each configuration, 10,000 simulation runs were
created. Table III shows the overall power and the
expected total sample sizes. Always, the truncation is
more powerful than the choice τ = 1, however, the differ-
ence in power is small. Furthermore, as in the case of k =
2, the expected total sample size is smaller when the trun-
cated product method is applied (α0 = 1). The decrease of
the expected total sample size is more pronounced for
larger values of k. Therefore, the truncation can be recom-
mended again. It reduces the expected total sample size
without a loss in power.
Discussion
In this section we only consider the case α = 0.025 and α0
= 1. The first example discussed in this section was pre-
sented by Bauer and Röhmel [6]. In a two-stage dose-
response study the effect of a new drug on blood pressure
was investigated. Assume that the trial would have started
with two medium doses. The p-value for the one-sided t
test between these two doses in the interim analysis was p1
= 0.206. Thus, the study continued with the comparison
placebo vs. a higher dose, and the second stage led to p2 =
0.0178. The product in the final analysis was p1p2  =
0.00367, the corresponding overall p-value of the non-
truncated product test is 0.024. Hence, the combination
test is significant even at the 0.025 level.
Figure 3 shows the overall p-value of the combination test
in case of truncation. Note that TPM p-values may be cal-
culated using a C++ code offered by Zaykin et al. [7] which
is available at ftp://statgen.ncsu.edu/pub/zaykin/tpm, in
addition, the method is implemented in the SAS proce-
dure psmooth. There is no large influence of τ as long as
this truncation point is larger than max(p1,p2). When τ is
slightly smaller than max(p1,p2), i.e. for τ → max(p1,p2)
with τ < max(p1,p2), the p-value reaches a local maximum
of 0.061. For τ < min(p1,p2) the p-value equals 1. Hence, a
too small choice of τ is risky. Thus, the analysis of this
example may be a further indication that the choice τ =
0.5 is reasonable. In fact, in this example any τ > 0.206
would have been a powerful alternative to Fisher's
criterion.
The second example is a hypothetical clinical study with
two stages. We consider a scenario as Bauer and Köhne
[[4], p. 1038] in their example. A clinical trial investigates
a new therapy for an indication in which no efficient
standard therapy is available. For the first stage five indi-
vidual endpoints have been selected. The first stage's sam-
ple size is 30 each in the therapy and the control group.
The changes to the baseline measurements of the five end-
points were combined into a single generalized least
squares (GLS) criterion according to O'Brien [12], and the
first stage's p-value was p1 = 0.1758. Hence, the study
continued.
For the second stage the set of five endpoints may be
reduced for different reasons such as observed effects and
variability, burden to the patients, and costs. The test sta-
tistic for the second stage was again the corresponding
GLS criterion. In this example, this led to a p-value of a
similar magnitude as in the first stage: p2 = 0.1517. There-
fore, in the final analysis we have p1p2 = 0.0267, and the
corresponding overall p-value is 0.1233 when Fisher's
Table 3: Simulated power to reject H0 and expected total sample 
sizes in three- and four-stage designs with α0 = 1 (50 observations 
per group and stage, combination of t tests, one-sided, α = 0.05)
δ = 0.1 0.2 0.3 0.4 0.5
3 stages
Overall power τ = 1 0.198 0.498 0.789 0.950 0.993
τ = 0.5 0.198 0.502 0.799 0.953 0.993
Expected total sample τ = 1 293.3 278.7 250.0 213.7 179.6
size τ = 0.5 292.7 276.9 247.1 209.9 176.1
4 stages
Overall power τ = 1 0.230 0.590 0.883 0.984 0.999
τ = 0.5 0.233 0.596 0.888 0.985 0.999
Expected total sample τ = 1 389.0 360.0 308.5 254.1 207.6
size τ = 0.5 387.6 356.2 302.5 246.8 202.3
The overall p-value of the final analysis based on the combi- nation of p1 = 0.206 and p2 = 0.0178 (first example) in  dependence of the truncation point τ Figure 3
The overall p-value of the final analysis based on the combi-
nation of p1 = 0.206 and p2 = 0.0178 (first example) in 
dependence of the truncation point τ. The horizontal refer-
ence line corresponds to Fisher's product criterion.
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original product test is applied. The overall p-values for
different choices of τ are displayed in Table IV. Here, the
TPM gives a smaller overall p-value than Fisher's method
for all considered values of the truncation point with the
exception of τ = 0.1. However, that value is smaller than
min(p1, p2). In this example α0 = 1 may be appropriate
because no efficient standard therapy is available, the
sample size of stage 1 is relatively small, and there might
be only one endpoint showing a difference between the
therapy and the control group.
Conclusion
The application of the truncated product method instead
of Fisher's combination test within an adaptive design
hardly changes the overall power. Therefore, to decide
whether or not a truncation is useful one should focus on
the probability to stop early and on the expected total
sample size. According to these criteria, a truncation
seems to be preferable in case of α0 = 1, but not for α0 < 1.
A variety of other combination functions exists [13], for
example, the inverse normal method was proposed for
adaptive designs [14]. According to Rice [15] Fisher's test
is "inappropriate when asking whether a set of tests, on
balance, supports or refutes a common null hypothesis ...
because ... Fisher's statistic is more sensitive to smaller, as
compared to larger, P-values" [[15], p. 303–305]. In con-
trast, the inverse normal method is not differentially
sensitive to data that support or refute a common null
hypothesis. Thus, one may argue that the inverse normal
method is more appropriate for an adaptive design if each
stage tests the same null hypothesis. However, in the con-
text of a dose-response study, discussed here as a motiva-
tion for α0 = 1, different doses may be tested in different
stages, that is, the hypotheses tested change. The resultant
question is whether at least one stage is significant, and a
high sensitivity to small p-values is desirable. Conse-
quently, Fisher's test or TPM are appropriate. An addi-
tional advantage of these two combination methods is
that an early termination with rejection of the null
hypothesis is possible with α0 = 1 and a full level α com-
bination test at the end.
There is also some literature related to the efficiency of
adaptive designs, and to the choice of combination func-
tions. Wassmer [16], for example, compared Fisher's
product criterion with an alternative adaptive design pro-
posed by Proschan and Hunsberger [17] based on a con-
ditional power function. Wassmer [16] concluded that
"no substantial differences between the procedures were
found in terms of rejection regions, power, and expected
sample sizes". One of the first to investigate optimal adap-
tive designs for the control of conditional power were
Brannath and Bauer [18]. They constructed two-stage
designs with overall and conditional power, which
minimize the expected sample size for different specifica-
tions of the alternative. It transpires that there is a variety
of different options to combine P-values and there is no
consensus on the best method to use. In this paper we
improve under special conditions Fisher's combination
test using the truncated product method.
It is worthwhile to note that the truncation point τ must
be specified a priori in the study protocol. Unless deter-
mined a priori, the truncated product method can be mis-
used to alleviate an observed significance. A post-hoc
choice based on the observed maximum of the individual
p-values is therefore not permitted. As discussed above, τ
= 0.5 may be a suitable choice. A further argument for this
choice is that those p-values are excluded from the product
that indicate a difference in the unanticipated direction.
Note that the truncated product does not follow a χ2-dis-
tribution. Thus, a penalty results for the exclusion of large
p-values. Nevertheless, this exclusion can be advantageous
as demonstrated by Zaykin et al. [7] and above for the case
of adaptive designs.
For the presentation of the power a one-sided significance
level of α = 5% was chosen in this paper. However, com-
pletely analogous results can be found in case of α = 2.5%.
Regarding the choice of α for one-sided tests it is referred
to Neuhäuser [19].
Appendix
The power of a two-stage test according to Bauer and
Köhne [4], that is, a combination with τ = 1, is given e.g.
by Wassmer [[20], p. 833].
In case of truncation with τ = α0 > α the power is
Table 4: The overall p-value of the final analysis based on the 
combination of p1 = 0.1758 and p2 = 0.1517 (second example) in 
dependence of the truncation point τ, τ = 1 corresponds to 
Fisher's product criterion.
τ p-value for TPM
0.1 1
0.2 0.0801
0.3 0.0964
0.4 0.1064
0.5 0.1130
0.6 0.1174
0.7 0.1203
0.8 0.1221
0.9 0.1230
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where fδ denotes the respective density under the alterna-
tive δ [20]. In case of truncation with τ > α, but α0 = 1, the
power is
Wassmer [20] presented a SAS/IML program to calculate
the power for the two-stage test without truncation. Mod-
ifications of this program were used to calculate the differ-
ent powers given above.
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